Anaheim, California (May 26, 2015) -- Anaheim Clinical Trials (ACT), an adult and pediatric Phase I through Phase IV clinical research center with full-service CRO capabilities, announced that the company has been selected by ClinicalRM to be a subcontractor. ACT will support the initiative of the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH), to utilize Phase I Clinical Trial Centers for Therapeutics Against Infectious Diseases.
“ACT is currently enrolling its first NIAID–sponsored trial in healthy subjects. We are very excited to be selected by ClinicalRM and look forward to participate in this and other future government projects. ACT is well-suited to conduct these trials - we have extensive experience in infectious disease trials, such as vaccines in healthy subjects and complex trials in patient populations, including Hepatitis and HIV,” said Peter Winkle, M.D., F.A.C.G, F.A.C.P., C.P.I., ACT Medical Director and Principal Investigator.
About Anaheim Clinical Trials:
Anaheim Clinical Trials (ACT) is an adult and pediatric Phase I-IV clinical research center, located in southern California (Anaheim). In addition to healthy volunteers, ACT has been particularly successful in enrolling special patient populations, such as renal- and hepatic-impaired patients, and Japanese subjects for ethno-bridging trials. Our certified Principal Investigators have the expertise and interest in a wide variety of therapeutic areas, including GI, pain, metabolic/inflammation, infectious diseases, and respiratory. ACT has been recognized by our customers for excellent quality research, timeliness, high patient enrollment, and ease of doing business. For more information, please visit our website at www.act-trials.com.
Anaheim Clinical Trials Contact
Linda Gundaker, MBA, MT(ASCP)
Executive Director of Business Development
Phone: (610) 937-2006
lgundaker@act-trials.com
Help employers find you! Check out all the jobs and post your resume.
